Cell penetrating peptide conjugates and methods of use thereof
Disclosed are conjugates of an oligonucleotide and a peptide covalently bonded to the oligonucleotide or linked by a linker, the peptide comprising at least one cationic domain comprising at least 4 amino acid residues and at least one hydrophobic domain comprising at least 3 amino acid residues, with the proviso that the peptide comprises 7 to 40 amino acid residues in total and does not comprise any artificial amino acid residues; the oligonucleotide comprises a total of 12 to 40 contiguous nucleobases, wherein at least 12 contiguous nucleobases are complementary to a target sequence in the human dystrophin gene..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Europäisches Patentamt - (2023) vom: 26. Dez. Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
WOOD MATTHEW [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Sonstige Themen: |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-12-26, Last update posted on www.tib.eu: 2024-04-22, Last updated: 2024-04-26 |
---|
Patentnummer: |
CN117295525 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA000100730 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA000100730 | ||
003 | DE-627 | ||
005 | 20240426160207.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240315s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA000100730 | ||
035 | |a (EPA)CN117295525 | ||
035 | |a (EPA)74669201 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a WOOD MATTHEW |e verfasserin |4 aut | |
245 | 1 | 0 | |a Cell penetrating peptide conjugates and methods of use thereof |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2023-12-26, Last update posted on www.tib.eu: 2024-04-22, Last updated: 2024-04-26 | ||
520 | |a Disclosed are conjugates of an oligonucleotide and a peptide covalently bonded to the oligonucleotide or linked by a linker, the peptide comprising at least one cationic domain comprising at least 4 amino acid residues and at least one hydrophobic domain comprising at least 3 amino acid residues, with the proviso that the peptide comprises 7 to 40 amino acid residues in total and does not comprise any artificial amino acid residues; the oligonucleotide comprises a total of 12 to 40 contiguous nucleobases, wherein at least 12 contiguous nucleobases are complementary to a target sequence in the human dystrophin gene. | ||
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a che | |
650 | 4 | |a 615 | |
700 | 0 | |a MANZANO RAQUEL |e verfasserin |4 aut | |
700 | 0 | |a GODFREY CAROLINE |e verfasserin |4 aut | |
700 | 0 | |a MCCLORY GRAHAM |e verfasserin |4 aut | |
700 | 0 | |a RAZ RICHARD |e verfasserin |4 aut | |
700 | 0 | |a GUETTER MICHAEL |e verfasserin |4 aut | |
700 | 0 | |a ARZUMANOV ANDREY |e verfasserin |4 aut | |
700 | 0 | |a O 'DONOVAN LIZ |e verfasserin |4 aut | |
700 | 0 | |a HAZELL GARETH |e verfasserin |4 aut | |
700 | 0 | |a HOLLAND ASHLYN |e verfasserin |4 aut | |
700 | 0 | |a VARELA MIGUEL |e verfasserin |4 aut | |
700 | 0 | |a BANERJEE SUHAS |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 26. Dez. |
773 | 1 | 8 | |g year:2023 |g day:26 |g month:12 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/74669201/publication/CN117295525A1?q=CN117295525 |x 0 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
951 | |a AR | ||
952 | |j 2023 |b 26 |c 12 |